S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Price, News & Analysis

$16.40
+0.10 (+0.61%)
(As of 03/28/2024 ET)
Today's Range
$15.84
$16.78
50-Day Range
$12.68
$20.00
52-Week Range
$10.38
$20.67
Volume
128,535 shs
Average Volume
131,132 shs
Market Capitalization
$861.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Tyra Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
34.1% Upside
$22.00 Price Target
Short Interest
Bearish
13.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Tyra Biosciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$298,165 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.95) to ($2.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

Medical Sector

804th out of 938 stocks

Pharmaceutical Preparations Industry

367th out of 425 stocks

TYRA stock logo

About Tyra Biosciences Stock (NASDAQ:TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Stock Price History

TYRA Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $16.10
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
TYRA Mar 2024 20.000 call
TYRA Mar 2024 20.000 put
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$28.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+34.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-69,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Miscellaneous

Free Float
42,857,000
Market Cap
$858.70 million
Optionable
Optionable
Beta
1.19
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Todd Harris Ph.D. (Age 45)
    Co-Founder, President, CEO, Secretary, Treasurer & Director
    Comp: $903.33k
  • Mr. Daniel Bensen (Age 48)
    Co-Founder & COO
    Comp: $630.8k
  • Mr. Ali D. Fawaz J.D.
    General Counsel & Secretary
  • Mr. Alan Fuhrman (Age 67)
    Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 68)
    Chief Technology Officer
  • Dr. Ronald V. Swanson Ph.D. (Age 60)
    Chief Scientific Officer
    Comp: $536.19k
  • Ms. Sarah Honig
    Vice President of Corporate Development & Strategy
  • Dr. Hiroomi Tada M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $519.65k
  • Dr. Piyush R. Patel Ph.D. (Age 58)
    Chief Development Officer
  • Amy Conrad
    Investor Contact

TYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TYRA shares.
View TYRA analyst ratings
or view top-rated stocks.

What is Tyra Biosciences' stock price target for 2024?

3 brokers have issued 12-month target prices for Tyra Biosciences' stock. Their TYRA share price targets range from $15.00 to $28.00. On average, they expect the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 34.1% from the stock's current price.
View analysts price targets for TYRA
or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2024?

Tyra Biosciences' stock was trading at $13.85 at the beginning of the year. Since then, TYRA stock has increased by 18.4% and is now trading at $16.40.
View the best growth stocks for 2024 here
.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TYRA earnings forecast
.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.33.

What ETF holds Tyra Biosciences' stock?

Range Cancer Therapeutics ETF holds 7,883 shares of TYRA stock, representing 1.17% of its portfolio.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (2.38%), Vanguard Group Inc. (1.76%), Vanguard Group Inc. (1.76%), Kynam Capital Management LP (0.79%), Northern Trust Corp (0.35%) and Wellington Management Group LLP (0.24%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends
.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TYRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners